Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success

Nov 17 2016

• By Mandy Jackson

Watch gears up close

Related Content

Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs

Sep 02 2015

Speed Is Everything In CGRP Race As Amgen/Novartis Reveal Phase III Data

Sep 30 2016

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Sep 30 2016

Related Companies

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Alder Biopharmaceuticals, Inc.

Eli Lilly and Company

Allergan plc

Additional Topics

Clinical Trials Companies Neurology BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window